Literature DB >> 6871766

Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

P H Reitsma, O L Bijvoet, M Potokar, L J van der Wee-Pals, M M van Wijk-van Lennep.   

Abstract

The effects of 1.5-2 years oral administration of disodium (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) on bone metabolism were studied in male and female rats. APD was mixed in the food at levels of 500, 2,000 and 10,000 ppm. A dose-dependent increase in metaphyseal bone was found, indicative of continued inhibition of bone and cartilage resorption. APD did not affect mineralization of bone and cartilage, primary bone formation, or periosteal apposition. A short-term metabolic balance study was performed to compare the effects of oral with subcutaneous APD. Absorption of APD was in the order of 0.2%. Oral APD increased absorption of phosphate, probably by complexation of calcium with APD. The excess absorbed phosphate increased phosphaturia and decreased urinary calcium.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6871766     DOI: 10.1007/bf02405058

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  11 in total

1.  METABOLIC STUDIES IN PATIENTS WITH HYPERCALCIURIA.

Authors:  A M PARFITT; B A HIGGINS; J R NASSIM; J A COLLINS; A HILB
Journal:  Clin Sci       Date:  1964-12       Impact factor: 6.124

2.  Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone.

Authors:  P J Meunier; M C Chapuy; C Alexandre; C Bressot; C Edouard; C Vignon; L Mathieu; U Trechsel
Journal:  Lancet       Date:  1979-09-08       Impact factor: 79.321

3.  Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  W B Frijlink; O L Bijvoet; J te Velde; G Heynen
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

4.  APD in Paget's disease of bone. Role of the mononuclear phagocyte system?

Authors:  O L Bijvoet; W B Frijlink; K Jie; H van der Linden; C J Meijer; H Mulder; H C van Paassen; P H Reitsma; J te Velde; E de Vries; J P van der Wey
Journal:  Arthritis Rheum       Date:  1980-10

5.  Dichloromethylene diphosphonate and calcium and phosphate metabolism.

Authors:  P H Reitsma; W B Frijlink; O L Bijvoet
Journal:  N Engl J Med       Date:  1980-07-17       Impact factor: 91.245

6.  Methyl-methacrylate as an embedding medium in histopathology.

Authors:  J T Velde; R Burkhardt; K Kleiverda; L Leenheers-Binnendijk; W Sommerfeld
Journal:  Histopathology       Date:  1977-09       Impact factor: 5.087

7.  Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment.

Authors:  R Smith; R G Russell; M C Bishop; C G Woods; M Bishop
Journal:  Q J Med       Date:  1973-04

8.  Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma.

Authors:  E S Siris; W H Sherman; D C Baquiran; J P Schlatterer; E F Osserman; R E Canfield
Journal:  N Engl J Med       Date:  1980-02-07       Impact factor: 91.245

9.  Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

10.  Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats.

Authors:  P H Reitsma; O L Bijvoet; H Verlinden-Ooms; L J van der Wee-Pals
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

View more
  10 in total

Review 1.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  Bone loss and bone blood flow in paraplegic rats treated with calcitonin, diphosphonate, and indomethacin.

Authors:  A Schoutens; M Verhas; N Dourov; P Bergmann; F Caulin; A Verschaeren; M Mone; A Heilporn
Journal:  Calcif Tissue Int       Date:  1988-02       Impact factor: 4.333

Review 3.  Bisphosphonates in osteoporosis?

Authors:  O L Bijvoet; R Valkema; C W Löwik; S E Papapoulos
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

4.  Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies?

Authors:  T Klenner; F Wingen; B K Keppler; B Krempien; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 5.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

6.  Mineral density gain in vertebrae of osteoporotic women on oral pamidronate reverts a year after treatment discontinuance.

Authors:  J R Zanchetta; H Plotkin; E J Roldán
Journal:  Calcif Tissue Int       Date:  1996-07       Impact factor: 4.333

7.  The bisphosphonates HEBP and AHPrBP but not AHBP inhibit mineral mobilization and lysosomal enzyme release from mouse calvarial bones in tissue culture.

Authors:  U Lerner; A Larsson
Journal:  Experientia       Date:  1984-09-15

8.  Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat.

Authors:  T Klenner; F Wingen; B Keppler; P Valenzuela-Paz; F Amelung; D Schmähl
Journal:  Clin Exp Metastasis       Date:  1990 Jul-Aug       Impact factor: 5.150

9.  Sodium EDTA enhances intestinal absorption of two bisphosphonates.

Authors:  M Janner; R C Mühlbauer; H Fleisch
Journal:  Calcif Tissue Int       Date:  1991-10       Impact factor: 4.333

10.  Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study.

Authors:  N W Clarke; I B Holbrook; J McClure; N J George
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.